Evaluation of cross-sectional and longitudinal changes in volumetric bone mineral density in postmenopausal women using single- versus dual-energy quantitative computed tomography

The Impact of Interventional Weight Loss on Bone Marrow Adipose Tissue in People Living with Obesity and Its Connection to Bone Metabolism

This review focuses on providing physicians with insights into the complex relationship between bone marrow adipose tissue (BMAT) and bone health, in the context of weight loss through caloric restriction or metabolic and bariatric surgery (MBS), in people living with obesity (PwO). We summarize the complex relationship between BMAT and bone health, provide an overview of noninvasive imaging techniques to quantify human BMAT, and discuss clinical studies measuring BMAT in PwO before and after weight loss. The relationship between BMAT and bone is subject to variations based on factors such as age, sex, menopausal status, skeletal sites, nutritional status, and metabolic conditions. The Bone Marrow Adiposity Society (BMAS) recommends standardizing imaging protocols to increase comparability across studies and sites, they have identified both water-fat imaging (WFI) and spectroscopy (1H-MRS) as accepted standards for in vivo quantification of BMAT. Clinical studies measuring BMAT in PwO are limited and have shown contradictory results. However, BMAT tends to be higher in patients with the highest visceral adiposity, and inverse associations between BMAT and bone mineral density (BMD) have been consistently found in PwO. Furthermore, BMAT levels tend to decrease after caloric restriction-induced weight loss. Although weight loss was associated with overall fat loss, a reduction in BMAT did not always follow the changes in fat volume in other tissues. The effects of MBS on BMAT are not consistent among the studies, which is at least partly related to the differences in the study population, skeletal site, and duration of the follow-up. Overall, gastric bypass appears to decrease BMAT, particularly in patients with diabetes and postmenopausal women, whereas sleeve gastrectomy appears to increase BMAT. More research is necessary to evaluate changes in BMAT and its connection to bone metabolism, either in PwO or in cases of weight loss through caloric restriction or MBS, to better understand the role of BMAT in this context and determine the local or systemic factors involved.

Osteoporosis and Bone Marrow Adipose Tissue

PURPOSE OF REVIEW

This review focuses on the recent findings regarding bone marrow adipose tissue (BMAT) concerning bone health. We summarize the variations in BMAT in relation to age, sex, and skeletal sites, and provide an update on noninvasive imaging techniques to quantify human BMAT. Next, we discuss the role of BMAT in patients with osteoporosis and interventions that affect BMAT.

RECENT FINDINGS

There are wide individual variations with region-specific fluctuation and age- and gender-specific differences in BMAT content and composition. The Bone Marrow Adiposity Society (BMAS) recommendations aim to standardize imaging protocols to increase comparability across studies and sites. Water-fat imaging (WFI) seems an accurate and efficient alternative for spectroscopy (¹H-MRS). Most studies indicate that greater BMAT is associated with lower bone mineral density (BMD) and a higher prevalence of vertebral fractures. The proton density fat fraction (PDFF) and changes in lipid composition have been associated with an increased risk of fractures independently of BMD. Therefore, PDFF and lipid composition could potentially be future imaging biomarkers for assessing fracture risk. Evidence of the inhibitory effect of osteoporosis treatments on BMAT is still limited to a few randomized controlled trials. Moreover, results from the FRAME biopsy sub-study highlight contradictory findings on the effect of the sclerostin antibody romosozumab on BMAT. Further understanding of the role(s) of BMAT will provide insight into the pathogenesis of osteoporosis and may lead to targeted preventive and therapeutic strategies.

Age and gender differences in vertebral bone marrow adipose tissue and bone mineral density, based on MRI and quantitative CT

PURPOSE

To investigate the age and gender differences in vertebral bone marrow adipose tissue (BMAT) and volumetric bone mineral density (vBMD).

METHOD

A total of 427 healthy adults, including 175 males (41 %) and 252 females (59 %) with an age range of 21-82 years, underwent MRI and quantitative CT examinations of the lumbar spine (L2-L4), and the corresponding BMAT and vBMD values were measured. The age-related progressions of BMAT and vBMD in men and women were evaluated and compared.

RESULTS

In males, vertebral BMAT rose gradually throughout life, while in females, BMAT increased sharply between 41 and 60 years of age. In participants aged < 40 years, BMAT was greater in males compared to females (p ≤ 0.01), while after the age of 60, BMAT was higher in females (p < 0.05). In males, vBMD decreased gradually with age, while in females, there was a sharp decrease in vBMD after the age of 40 years. At age of 31-40 years, vBMD was higher in females (P < 0.002), while at age > 60 years, vBMD was higher in males (61-70 years, P < 0.01; > 70 years, P = 0.02).

CONCLUSIONS

We found significant age and gender differences in lumbar BMAT and vBMD. These findings will help to improve our understanding of the interaction between bone marrow fat content and bone mineral density in the ageing process.

Sources of error in bone mineral density estimates from quantitative CT

Bone mineral density (BMD) estimates from quantitative computed tomography (QCT) have proven useful for opportunistic screening of osteoporosis, treatment monitoring, and bone strength measurement. These estimates are subject to bias and variance from a variety of sources related to the imaging equipment, methods applied in the estimation procedure, and the patients themselves. In this article, we review the literature to describe the sources and sizes of error in spine and hip BMD estimates from single-energy QCT that can result from factors related to the scanner, imaging techniques, imaging subject, calibration phantom, and calibration approach. We also describe the baseline variance that can be expected based on repeatability and reproducibility studies. Though reproducible BMD estimates may be achievable with QCT, a thorough understanding of the potential sources of error and their size relative to the diagnostic task is essential to their appropriate and meaningful interpretation.

Upper Extremity Fragility Fractures

The population of elderly patients is rapidly increasing in the United States and worldwide, leading to an increased prevalence of osteoporosis and a concurrent rise in fragility fractures. Fragility fractures are defined as fractures involving a low-energy mechanism, such as a fall from a standing height or less, and have been associated with a significant increase in the risk of a future fragility fracture. Distal radius fractures in the elderly often present earlier than hip and vertebral fractures and frequently involve underlying abnormalities in bone mass and microarchitecture. This affords a unique opportunity for upper extremity surgeons to aid in the diagnosis and treatment of osteoporosis and the prevention of secondary fractures. This review aims to outline current recommendations for orthopedic surgeons in the evaluation and treatment of upper extremity fragility fractures.

Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study

In postmenopausal women at high risk of fracture, we previously reported that combined denosumab and high-dose (HD; 40 μg) teriparatide increased spine and hip bone mineral density (BMD) more than combination with standard-dose teriparatide (SD; 20 μg). To assess the effects of these combinations on bone microarchitecture and estimated bone strength, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and distal tibia in these women, who were randomized to receive either teriparatide 20 μg (n = 39) or 40 μg (n = 37) during months 0 to 9 overlapped with denosumab 60 mg s.c. given at months 3 and 9, for a 15-month study duration. The 69 women who completed at least one study visit after baseline are included in this analysis. Over 15 months, increases in total BMD were higher in the HD-group than the SD-group at the distal tibia (5.3% versus 3.4%, p = 0.01) with a similar trend at the distal radius (2.6% versus 1.0%, p = 0.06). At 15 months, cortical porosity remained similar to baseline, with absolute differences of -0.1% and -0.7% at the distal tibia and -0.4% and -0.1% at the distal radius in the HD-group and SD-group, respectively; p = NS for all comparisons. Tibial cortical tissue mineral density increased similarly in both treatment groups (1.3% [p < 0.0001 versus baseline] and 1.5% [p < 0.0001 versus baseline] in the HD-group and SD-group, respectively; p = 0.75 for overall group difference). Improvements in trabecular microarchitecture at the distal tibia and estimated strength by micro-finite element analysis at both sites were numerically greater in the HD-group compared with SD-group but not significantly so. Together, these findings suggest that short-term treatment combining denosumab with either high- or standard-dose teriparatide improves HR-pQCT measures of bone density, microstructure, and estimated strength, with greater gains in total bone density observed in the HD-group, which may be of benefit in postmenopausal women with severe osteoporosis. © 2020 American Society for Bone and Mineral Research (ASBMR).

A Contemporary View of the Diagnosis of Osteoporosis in Patients With Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the axial joints. Altered bone metabolism associated with chronic inflammation leads to both new bone formation in the spine and increased bone loss. It is known that patients with axSpA have a high prevalence of osteoporosis and fractures. However, there is no consensus on which imaging modality is the most appropriate for diagnosing osteoporosis in axSpA. Bone mineral density measurement using dual-energy X-ray absorptiometry is the primary diagnostic method for osteoporosis, but it has notable limitations in patients with axSpA. This method may lead to the overestimation of bone density in patients with axSpA because they often exhibit abnormal calcification of spinal ligaments or syndesmophytes. Therefore, the method may not provide adequate information about bone microarchitecture. These limitations result in the underdiagnosis of osteoporosis. Recently, new imaging techniques, such as high-resolution peripheral quantitative computed tomography, and trabecular bone score have been introduced for the evaluation of osteoporosis risk in patients with axSpA. In this review, we summarize the current knowledge regarding imaging techniques for diagnosing osteoporosis in patients with axSpA.

Advanced Quantitative Spine Imaging

Although advanced quantitative imaging may not be currently used to any degree in the routine reporting of spinal examinations, this situation will change in the not too distant future. Advanced quantitative imaging has already allowed us to understand a great deal more regarding spinal development, marrow physiology, and disease pathogenesis. Radiologists are ideally suited to drive this research forward. To speed up this process and optimize the impact of studies reporting spine quantitative data, we should work toward universal standards on the acquisition of spine data that will allow quantitative studies to be more easily compared, contrasted, and amalgamated.

MRI Assessment of Bone Marrow Composition in Osteoporosis

PURPOSE OF REVIEW

To provide an overview on recent technical development for quantifying marrow composition using magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques, as well as a summary on recent findings of interrelationship between marrow adipose tissue (MAT) and skeletal health in the context of osteoporosis.

RECENT FINDINGS

There have been significant technical advances in reliable quantification of marrow composition using MR techniques. Cross-sectional studies have demonstrated a negative correlation between MAT and bone, with trabecular bone associating more strongly with MAT than cortical bone. However, longitudinal studies of MAT and bone are limited. MAT contents and composition have been associated with prevalent vertebral fracture. The evidence between MAT and clinical fracture is more limited, and, to date, no studies have reported on the relationship between MAT and incident fracture. Increasing evidence suggests a dynamic role of marrow fat in skeletal health. Reliable non-invasive quantification of marrow composition will facilitate developing novel treatment strategies for osteoporosis.

Dual-energy estimates of volumetric bone mineral densities in the lumbar spine using quantitative computed tomography better correlate with fracture properties when compared to single-energy BMD outcomes

It is estimated that over 200 million people worldwide are affected by osteoporosis. Vertebral fracture risk prediction using dual energy x-ray absorptiometry (DXA) is confounded by limitations of the technology, such as 2D measurements of bone mineral density (BMD), inability to measure bone distribution and heterogeneity, and potential overestimations of BMD due to degenerative diseases. To overcome these shortcomings, single energy (SE) quantitative computed tomography (QCT) imaging estimates of Hounsfield units (HU) and volumetric BMD have been implemented as alternative methodologies for assessing fracture risk. However, marrow fat within the vertebrae can highly affect the vBMD and fracture properties estimations. To address this issue, 54 vertebrae were dissected from nine cadaveric spines and scanned using SE-QCT (120kVp) and dual energy (DE)-QCT (80/140 kVp), with the latter accounting for marrow fat within the vertebrae. The vertebrae were then scanned using DXA and subjected to mechanical testing to obtain fracture properties. aBMD outcomes from DXA showed a better correlation with DE-QCT vBMD versus SE outcomes [DE: aBMD vs. vBMD (R²: 0.61); SE: aBMD vs. vBMD (R²: 0.27)]. SE-QCT underestimated vertebral vBMD by -56% (p<0.0001) when compared to DE-QCT. vBMD estimates from SE-QCT could predict 45% and 37% of the vertebral failure loads and stiffness, respectively, compared to 67% and 46% from DE-QCT. DE-QCT vBMD outcomes highly correlated with fracture properties of vertebrae as compared to SE-QCT metrics. As DE scanning has the ability to correct for the effects of bone marrow fat, estimated vBMD from SE-QCT were significantly underestimated compared to DE-QCT. Dual energy CT scanning has the potential to more accurately predict vertebral failure and aid the clinician in the evaluation of appropriate interventions. Future studies should consider implementing DE-QCT in their fracture assessment.

Quantitative accuracy and dose efficiency of dual-contrast imaging using dual-energy CT: a phantom study

PURPOSE

To evaluate the quantitative accuracy and dose efficiency of simultaneous imaging of two contrast agents using dual-energy computed tomography (DECT), two imaging tasks each representing one potential clinical application were investigated in a phantom study: biphasic liver imaging with iodine and gadolinium, and small bowel imaging with iodine and bismuth.

METHODS

To separate and quantify mixtures of two contrast agents using a single DECT scan, mixed iodine and gadolinium samples were prepared with the contrast enhancement values corresponding to the late arterial (iodine) and the portal-venous (gadolinium) phase for biphasic liver imaging. Mixed iodine and bismuth samples were prepared mimicking the arterial (iodine) and the enteric (bismuth) enhancement for small bowel imaging. For comparison to the reference condition of performing two single-energy CT (SECT) scans, contrast samples were prepared separately to mimic separate scans in the arterial/venous phase and arterial/enteric enhancement. Samples were placed in a 35 cm wide water tank and scanned using a third-generation dual-source DECT scanner with three tube potential pairs: 80/Sn150, 90/Sn150, and 100/Sn150 kV, all with default dose partitioning between two x-ray beams to acquire DECT data. The same scanner operated in a single-energy mode acquired SECT data (120 kV). Total radiation dose (CTDIvol) was matched for the single-scan DECT and the two-scan SECT protocols. The DECT protocol was followed by a generic image-based three-material decomposition method to determine the material-specific images, based on which concentrations of each basis material were quantified and noise levels were measured. To compare with the SECT images directly acquired with the SECT protocol, the concentration values in each contrast-specific image were converted to CT numbers at 120 kV (i.e., virtual SECT (vSECT) images). The noise level and noise power spectra differences between the SECT and vSECT images were compared to evaluate the dose efficiency of the single-scan DECT protocol. The impact of dose partitioning in the DECT protocol on quantitative dual-contrast imaging performance was also studied.

RESULTS

For each imaging task, contrast materials were accurately quantified against the nominal concentrations using the DECT data with strong correlation (R²  ≥ 0.98 for both imaging tasks). Compared to the SECT protocol, the DECT protocol was not dose efficient. With the optimal x-ray tube potential pair 80/Sn150 kV, the noise level in vSECT images increased by 401%/488% (arterial/portal-venous) for the biphasic liver imaging task and by 10%/41% (arterial/enteric) for the small bowel imaging task compared to that in SECT images. The corresponding radiation dose increase is 2410%/3357% for the biphasic liver imaging task and 21%/99% for the small bowel imaging task, respectively, to achieve the same noise as that in SECT images. This could be improved by adjusting the dose partitioning in DECT.

CONCLUSIONS

DECT can be used to simultaneously separate and quantify two contrast materials. However, compared to a two-scan SECT protocol, much higher radiation dose is needed in a single-scan DECT protocol to achieve the same image noise, especially for tasks involving the dual contrast of iodine and gadolinium.

Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

BACKGROUND

In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD) than with either drug alone. We aimed to assess whether administration of denosumab with high dose teriparatide would stimulate larger increases in bone mass than those observed in the DATA study.

METHODS

DATA-HD was an open-label, randomised, controlled phase 4 trial done at Massachusetts General Hospital. Eligible women were postmenopausal women (at least 36 months since last menses or since hysterectomy with a follicle-stimulating hormone concentration of ≥40 U/L) with osteoporosis. Participants were randomly assigned (1:1) to receive teriparatide 20 μg (standard dose) or 40 μg (high dose) daily via subcutaneous injection for 9 months. At 3 months, both groups were started on denosumab 60 mg every 6 months via subcutaneous injection for 12 months. Areal BMD (aBMD) was measured at 0, 3, 9, and 15 months. Treatment was given open label, but outcome assessors were masked. The primary endpoint was percentage change from baseline in spine areal BMD (aBMD) at 15 months. Women who completed at least one study visit after baseline were included in the modified intention-to-treat analysis. Safety was assessed in all randomly assigned participants. This study is registered with ClinicalTrials.gov, number NCT02176382.

FINDINGS

Between Oct 15, 2014, and June 10, 2016, 269 women were assessed for eligibility. 76 participants were randomly assigned to 20 μg teriparatide (n=39) or 40 μg teriparatide (n=37), of whom 69 completed at least one post-baseline visit. At 15 months, mean spine aBMD had increased to a significantly greater extent in the 40 μg group (17·5% [SD 6·0] increase) than the 20 μg group (9·5% [3·2]; difference 8·1%, 95% CI 5·5 to 10·6, p<0·0001). Mean femoral neck aBMD had also increased to a greater extent in the 40 μg group (6·8% [SD 4·1] increase) than the 20 μg group (4·3% [3·7]; difference 2·5%, 0·5 to 4·5, p=0·04), as did mean total hip aBMD (40 μg group, 6·1% [3·4] increase; 20 μg group, 3·9% [2·9] increase; difference 2·2%, 0·6 to 3·8, p<0·0001). 30 (77%) of 39 participants in the 20 μg group and 29 (78%) of 37 participants in the 40 μg group had an adverse event, and seven (18%) and two (5%) patients had serious adverse events. The most frequent adverse events were joint pain (15 [38%]), muscle cramp (15 [38%]), and fatigue (12 [31%]) in the 20 μg group group and fatigue (14 [38%]), nausea (16 [43%]), and joint pain (17 [46%]) in the 40 μg group. No deaths were reported.

INTERPRETATION

Combined treatment with teriparatide 40 μg and denosumab increases spine and hip BMD more than standard combination therapy. This large and rapid increase in bone mass suggest that this high dose regimen might provide a method of restoring skeletal integrity in patients with osteoporosis.

FUNDING

National Institutes of Health and the Dart Foundation.

Fracture prediction, imaging and screening in osteoporosis

Osteoporosis is associated with increased fragility of bone and a subsequent increased risk of fracture. The diagnosis of osteoporosis is intimately linked with the imaging and quantification of bone and BMD. Scanning modalities, such as dual-energy X-ray absorptiometry or quantitative CT, have been developed and honed over the past half century to provide measures of BMD and bone microarchitecture for the purposes of clinical practice and research. Combined with fracture prediction tools such as Fracture Risk Assessment Tool (FRAX) (which use a combination of clinical risk factors for fracture to provide a measure of risk), these elements have led to a paradigm shift in the ability to diagnose osteoporosis and predict individuals who are at risk of fragility fracture. Despite these developments, a treatment gap exists between individuals who are at risk of osteoporotic fracture and those who are receiving therapy. In this Review, we summarize the epidemiology of osteoporosis, the history of scanning modalities, fracture prediction tools and future directions, including the most recent developments in prediction of fractures.

Osteoarthritis Changes Hip Geometry and Biomechanics Regardless of Bone Mineral Density—A Quantitative Computed Tomography Study

We aimed to compare proximal femur geometry and biomechanics in postmenopausal women with osteoarthritis (OA) and/or osteoporosis (OP), using quantitative computed tomography (QCT). A retrospective analysis of QCT scans of the proximal femur of 175 postmenopausal women was performed. Morphometric and densitometric data of the proximal femur were used to evaluate its biomechanics. We found, 21 had a normal bone mineral density (BMD), 72 had osteopenia, and 81 were diagnosed with OP. Radiographic findings of hip OA were seen in 43.8%, 52.8%, and 39.5% of the normal BMD, osteopenic, and OP groups, respectively (p < 0.05). OA was significantly correlated with total hip volume (r = 0.21), intertrochanteric cortical volume (r = 0.25), and trochanteric trabecular volume (r = 0.20). In each densitometric group, significant differences in hip geometry and BMD were found between the OA and non-OA subgroups. Hip OA and OP often coexist. In postmenopausal women, these diseases coexist in 40% of cases. Both OA and OP affect hip geometry and biomechanics. OA does so regardless of densitometric status. Changes are mostly reflected in the cortical bone. OA leads to significant changes in buckling ratio (BR) in both OP and non-OP women.

Impact of prior information on material decomposition in dual- and multienergy computed tomography

Prior information is often included in the basis material decomposition to solve the quantification problem of three-material mixtures in dual-energy computed tomography (DECT). Multienergy computed tomography (MECT) with more than two energy bins can provide a sufficient solution to this problem without invoking additional prior information. However, a question remains as to whether the prior information should still be included in the material decomposition process using MECT to improve the quantification accuracy and control noise amplification. This study aims to evaluate the impact of the prior information on noise and quantification bias in both DECT and MECT. The material decomposition tasks we used in this study are to quantify water/iodine, water/iodine/gadolinium, and water/ iodine/calcium in two- and three-material decompositions, under the assumption that the object to be decomposed consists of the basis materials and their mixtures. We performed phantom simulation and experimental studies using a clinical DECT system and a research photon-counting-detector-based MECT system. Results in the current phantom studies show that the prior information can still improve the noise performance without substantially affecting the basis material quantitative accuracy during the material decomposition process, even when the number of x-ray energy beams/bins is equal or greater than the number of basis materials.

Correction of QCT vBMD using MRI measurements of marrow adipose tissue

OBJECTIVE

Quantitative computed tomography (QCT) measurements of volumetric bone mineral density (vBMD) are subject to errors due to variations in the amount of bone marrow adipose tissue (BMAT). The purpose of our study was to describe and validate a novel method to correct lumbar spine trabecular vBMD measurements for BMAT using chemical shift-encoded magnetic resonance imaging (CSE-MRI).

METHODS

CSE-MRI measurements of proton density fat fraction (PDFF) were used to correct QCT spine vBMD measurements for BMAT based on the H₂O and K₂HPO₄ basis set equivalent densities of bone, red and yellow bone marrow. BMAT corrected and uncorrected vBMD measurements of the L1 vertebra were compared with dual-energy QCT (DEQCT) measurements in 18 subjects (mean age: 68 y, range 60 to 93 y). A further 400 subjects (mean age: 53 y, range 21 to 82 y) had 120 kV_p single-energy QCT and CES-MRI scans of L2-L4 and the data used to simplify the adipose tissue correction by deriving a linear equation between the CSE-MRI vBMD correction and fractional BMAT content.

RESULTS

Application of the CSE-MRI derived vBMD correction changed the bias (95% limits of agreement) compared with DEQCT from 26.7 (11.0 to 42.4) mg/cm³ to 2.2 (-9.5 to 13.9) mg/cm³ at 80 kV_p, and from 22.4 (3.3 to 41.6) mg/cm³ to 2.9 (-12.6 to 18.4) mg/cm³ at 120 kV_p. Data for the 400 subjects gave the following relationship valid at 120 kV_p: vBMD correction (mg/cm³) = -12.96 + 75.76 × BMAT.

CONCLUSION

CSE-MRI measurements of PDFF can be used to correct for BMAT content and improve the accuracy of lumbar spine QCT vBMD measurements calibrated using a K₂HPO₄ phantom.